New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 17, 2014
05:34 EDTGWPHGW Pharmaceuticals provides update on cannabinoid pipeline
GW Pharmaceuticals provided an update on the company's cannabinoid pipeline. GW has completed a Phase 1 clinical trial of GWP42006 to treat epilepsy. CBDV was well tolerated even at the highest tested dose and no significant side effects were observed. There were no serious or severe adverse events, nor any withdrawals due to adverse events, and all mild adverse events resolved on treatment. CBDV has shown the ability to treat seizures in pre-clinical models of epilepsy with significantly fewer side effects than currently approved anti-epileptic drugs1. CBDV also appears to employ a different mechanism of action to currently available anti-epileptic treatments. GW expects to commence a Phase 2 study of CBDV in patients with epilepsy later in 2014, using the doses identified as appropriate in this Phase 1 study. GW also announced that the Intellectual Property Office in the United Kingdom has granted a patent for the use of CBDV in the treatment of epilepsy, patent number GB2479153B. This same patent is currently in prosecution with the USPTO. GW has commenced a 12-week randomized, double blind, placebo controlled Phase 2b study of GWP42004 to treat Type 2 diabetes. The primary objective of this study is to compare the change in glycemic control in participants with Type 2 diabetes when treated with one of three doses of GWP42004 or placebo as add-on therapy to metformin with the primary endpoint being change from baseline to the end of treatment in mean glycosylated haemoglobin A1c level. The safety and tolerability of GWP42004 compared with placebo will also be assessed. This study is expected to enroll approximately 200 patients with an estimated completion date of the second half of 2015. GW has commenced a Phase 2a trial using GWP42003 to treat schizophrenia. GWP42003 has shown notable anti-psychotic effects in accepted pre-clinical models of schizophrenia and importantly has also demonstrated the ability to reduce the characteristic movement disorders induced by currently available anti-psychotic agents. The mechanism of GWP42003 does not appear to rely on the D2 receptor augmentation of standard antipsychotics and therefore has the potential to offer a novel treatment option in this therapeutic area.
News For GWPH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 30, 2015
07:58 EDTGWPHGW Pharmaceuticals re-initiated with a Buy at Roth Capital
Subscribe for More Information
November 20, 2015
06:01 EDTGWPHGW Pharmaceuticals selloff yesterday an overreaction, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says shares of GW Pharmaceuticals sold off yesterday in response to an abstract posted for the American Epilepsy Society conference in December describing a single center's experience with Epidiolex for seizures. The results support the drug's potent activity in Dravet syndrome, but some investors have concern with the drop-out rate due to inactivity and the lower response rate compared to what has otherwise been described for Epidiolex, Schimmer told investors last night in a research note titled "Over-Reacting To A Tree When The Forest Remains In Good Shape." The dropout rate is likely a result of the center's "highly questionable" practice of stopping drug if seizure reduction doesn't reach 50%, while the lower response rate at one site shouldn't detract from a "much bigger, robust clinical experience spanning multiple centers," Schimmer argues. He reiterates an Overweight rating on GW with a $147 price target. The stock closed yesterday down $5.42 to $82.30.
November 19, 2015
15:33 EDTGWPHGW Pharmaceuticals drops 10% after epilepsy study abstract posted
The conclusion of the abstract, posted to the the site of the American Epilepsy Society, stated: "Add-on pure CBD was associated with more than 50% seizure reduction in one-third of patients at 3 months...Best results were obtained in patients with Dravet syndrome, although one experienced a severe increase in seizure frequency."
15:31 EDTGWPHAbstract for GW Pharmaceuticals epilepsys study posted to AES site
Subscribe for More Information
November 16, 2015
07:16 EDTGWPHHayman Capital gives quarterly update on stakes
NEW STAKES: Impax (IPXL), CF Industries (CF), GW Pharmaceuticals (GWPH), ProNAi Therapeutics (DNAI). INCREASED STAKES: BioMarin (BMRN), NMI Holdings (NMIH), Vertex (VRTX), Endo (ENDP). DECREASED STAKES: Mylan (MYL). LIQUIDATED STAKES: Perrigo (PRGO), Oasis Petroleum (OAS), Whiting Petroleum (WLL), Newfield Exploration (NFX), SM Energy (SM).

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use